Jak léčit dyslipidemii u pacientů s renální insuficiencí
Výběr z doporučení KDIGO s klinickým komentářem

Czech version

Authors: J. Vachek; O. Zakiyanov; V. Tesař
Authors‘ workplace: Klinika nefrologie 1. LF UK a VFN v Praze
Published in: Kardiol Rev Int Med 2015, 17(4): 339-341
Category: Cardiology Review

Overview

The article contains current recommendations of the Lipid Work Group of The Kidney Disease: Improving Global Outcomes (KDIGO) organisation on lipid management and treatment of dyslipidaemias in patients with chronic kidney disease (CKD). To sum up, the current consensus is that dyslipidaemia in adult patients with CKD stages G3–G5 should be treated using statin or statin with ezetimibe. It is recommended not to initiate such therapy in dialysed patients, however, statin-based treatment should continue for patients who have already started such treatment during previous stages of renal insufficiency. The aim of this article is to provide a comprehensive review of current recommendations on lipid management in chronic kidney disease patients.

Keywords:
dyslipidaemia – chronic kidney disease – CKD – statins – fibrates – ezetimibe

Sources

1. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep 2015; 15: 340. doi: 10.1007/ s11886-012-0340-4.

2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154– 2169.

3. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85– 97.

4. Baigent C, Landray MJ, Reith C et al. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181– 2192. doi: 10.1016/ S0140-6736(11)60739-3.

5. Matsushita K, van der Velde M, Astor BC et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073– 2081. doi: 10.1016/ S0140-6736(10)60674-5.

6. Wanner C, Krane V, März W et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238– 248.

7. März W, Genser B, Drechsler C et al. German Diabetes and Dialysis Study Investigators. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011; 6: 1316– 1325. doi: 10.2215/ CJN.09121010.

8. Fellström BC, Jardine AG, Schmieder RE et al. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395– 1407. doi: 10.1056/ NEJMoa0810177.

9. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO 2012 clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Supplements 2013; 3: 259– 305.

10. Smith HT, Jokubaitis LA, Troendle AJ et al. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993; 6 (11 Pt 2): 375S– 382S.

11. Kon V, Yang H, Fazio S. Residual cardiovascular risk in chronic kidney disease: Role of high-density lipoprotein. Arch Med Res 2015; 46: 379– 391. doi: 10.1016/ j.arcmed.2015.05.009.